OGP-CTx fusion protein for treating osteoporosis and relieving pain and nucleic acid encoding same
A fusion protein and osteoporosis technology, applied in the field of fusion protein and nucleic acid encoding the fusion protein, can solve problems such as inconvenience of patients, achieve the effects of less psychological burden, eliminating pain, and long treatment process
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach 1
[0012] Specific embodiment 1: The amino acid sequence of the OGP-CTx fusion protein used for the treatment of osteoporosis and analgesia in this embodiment is shown in SEQ ID NO:2.
[0013] The nucleic acid sequence of the OGP-CTx fusion protein used in the treatment of osteoporosis and analgesia in this embodiment is shown in SEQ ID NO: 1. The nucleic acid sequence was synthesized by a bioengineering company to produce a plasmid vector pUC ( OGP / CTx). The pUC (OGP / CTx) vector was digested with BamH I and EcoRI. (The digestion reaction system is shown in Table 1. The digestion reaction was reacted at 37°C for 10 hours, then 1.5% agarose gel electrophoresis, the target fragment Purified and recovered with DNA GEL EXTRACTION KIT), and digested pGEX-6P-1 with BamHI and EcoRI (the digestion reaction system is shown in Table 2, and the digestion reaction was reacted at 37°C for 10 hours, and then 0.6% agarose gel Electrophoresis, the target fragment is purified and recovered with DNA...
specific Embodiment approach 2
[0060] Embodiment 2: The nucleic acid sequence of the OGP-CTx fusion protein used in the treatment of osteoporosis and analgesia in this embodiment is shown in SEQ ID NO:1.
[0061] The nucleic acid sequence of the OGP-CTx fusion protein used in the treatment of osteoporosis and analgesia in this embodiment is synthesized by a bioengineering company.
[0062] In this embodiment, the nucleic acid sequence of the OGP-CTx fusion protein used to treat osteoporosis and analgesia inserts a KpnI restriction site between OGP and CTx, which can not only improve the stability of the encoded fusion protein, but also change the fusion protein. Its secondary structure improves its biological performance.
[0063] In this embodiment, BamHI and EcoRI restriction sites are added on both sides of the fusion protein gene, and the coding base sequence of the fusion gene is redesigned according to the characteristics of E. coli preferred codons.
[0064]
[0065]
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


